1. In Vivo
  2. >>Market Access

Medicare In The Business Of Setting ‘Fair’ Drug Prices: How Will Value Factor In?

 
• By Cathy Kelly

New law directs HHS to consider comparative effectiveness information as it approaches price negotiations with manufacturers. But it’s not clear what that means and stakeholders will watch for greater clarity from implementing regulations. ICER’s Steve Pearson weighs in on what they might say.    

Biden
Joe Biden signed the Inflation Reduction Act on 16 August • Source: Shutterstock

New law directs HHS to consider comparative effectiveness information as it approaches price negotiations with manufacturers. But it’s not clear what that means and stakeholders will watch for greater clarity from implementing regulations. ICER’s Steve Pearson weighs in on what they might say.

For the first time, a law enacted in the US authorizes the Health and Human Services Department to set drug...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.

Q&A: Commercializing Oncology Products, Strategic Insights For Drug Developers

 
• By Jo Shorthouse

John Arena, president of Global Pharma Services at Cencora, talks to In Vivo about how companies can strategize market entry for oncology products.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 
• By Bridget Silverman

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

More from In Vivo

Podcast: Poolbeg CEO On The Biotech’s Big Bet On Small Molecules

 
• By Jo Shorthouse

In the latest episode of the In Vivo Podcast, Jeremy Skillington, CEO of Poolbeg Pharma, discussed the company’s ambitious pipeline and strategic direction.

video
Sponsored by:

Meeting the demands of the global biologics market

Lonza is addressing the growing global demand for biologics by utilizing its expert teams and the advanced capabilities of its newly acquired large-scale manufacturing site in Vacaville, California. Joanna McCafferty, Director of Commercial Development, shares more in this brief video. Ask ChatG

Mapping The Power And Potential Of Europe’s Market Access Collaborations

 
• By Leela Barham

Understand who’s influencing access decisions and how pharma can engage strategically across the continent.